These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28318221)

  • 21. Sequence-to-structure dependence of isolated IgG Fc complex biantennary N-glycans: a molecular dynamics study.
    Harbison AM; Brosnan LP; Fenlon K; Fadda E
    Glycobiology; 2019 Jan; 29(1):94-103. PubMed ID: 30325416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
    Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
    Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of stage-dependent glycans on the Fc domains of IgG antibodies of ALS animals.
    Edri-Brami M; Sharoni H; Hayoun D; Skutelsky L; Nemirovsky A; Porgador A; Lichtenstein RG
    Exp Neurol; 2015 May; 267():95-106. PubMed ID: 25725350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.
    Krapp S; Mimura Y; Jefferis R; Huber R; Sondermann P
    J Mol Biol; 2003 Jan; 325(5):979-89. PubMed ID: 12527303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.
    Yu X; Baruah K; Harvey DJ; Vasiljevic S; Alonzi DS; Song BD; Higgins MK; Bowden TA; Scanlan CN; Crispin M
    J Am Chem Soc; 2013 Jul; 135(26):9723-32. PubMed ID: 23745692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions.
    Crispin M; Bowden TA; Coles CH; Harlos K; Aricescu AR; Harvey DJ; Stuart DI; Jones EY
    J Mol Biol; 2009 Apr; 387(5):1061-6. PubMed ID: 19236877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
    Lee HS; Im W
    Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural characterization of the Man5 glycoform of human IgG3 Fc.
    Shah IS; Lovell S; Mehzabeen N; Battaile KP; Tolbert TJ
    Mol Immunol; 2017 Dec; 92():28-37. PubMed ID: 29031045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
    Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
    Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of glycan truncation on Fc structural integrity.
    Buck PM; Kumar S; Singh SK
    MAbs; 2013; 5(6):904-16. PubMed ID: 24492344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Fc-Glycan Structure on the Conformational Stability of IgG Revealed by Hydrogen/Deuterium Exchange and Limited Proteolysis.
    Fang J; Richardson J; Du Z; Zhang Z
    Biochemistry; 2016 Feb; 55(6):860-8. PubMed ID: 26812426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
    Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
    J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
    Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
    Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
    J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structure of deglycosylated human IgG4-Fc.
    Davies AM; Jefferis R; Sutton BJ
    Mol Immunol; 2014 Nov; 62(1):46-53. PubMed ID: 24956411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.